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from 2006-2011 for persons 45 years of age and older were included if COPD was 
the principal diagnosis. Inpatient and outpatient event rates per 1,000 persons by 
sex were calculated for each observation year in Iowa. The changes in rates over 
time were estimated using ANOVA. RESULTS A total of 34,118 inpatient events 
studied; 17,866 (52.37%) were for women; 9,943(29.14%) were for persons under 65 
years of age. Of the 33,070 outpatient events studied, 16,200(48.99%) were for 
women; 13,308(40.24%) were for persons under 65 years of age. Annual inpatient 
event rates per 1000 persons were not significantly different across 6 years (P-
value=0.30); outpatient event rates per 1000 persons significantly increased over 
time (P-value=0.0061). For inpatient and outpatient events, women had 
significantly lower rates per year (P-value<0.0001). However, the gap between 
males and females narrowed over time for both types of events. The absolute 
difference in rates between men and women for inpatient events declined from 
1.12 per 1000 persons in 2006 to 0.47 per 1000 persons in 2011. For outpatient 
events, the absolute difference in rates declined from 2.08 per 1000 persons in 
2006 to 0.96 per ,000 persons in 2011. CONCLUSIONS There is a changing profile 
of COPD in Iowa. An increasing number of women and persons younger than 65 
years of age experienced hospitalizations and outpatient visits. Approximately 
one out of three COPD hospital events and two out of five outpatient events 
occurred among persons of working age (<65). Greater emphasis should be given 
to the impact of the disease for women and the economic burden for the US 
work force.  
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HOUSEHOLD EXPENDITURE ON PEDIATRIC ATOPIC DERMATITIS ACROSS 12 
COUNTRIES IN THE ASIA PACIFIC REGION  
Azmi S1, Goh A2 
1Veras Research, Kelana Jaya, Malaysia, 2Azmi Burhani Consulting, Petaling Jaya, Malaysia  
OBJECTIVES: Atopic dermatitis (AD), also known as eczema, is a common 
chronic skin condition in childhood that has a negative impact on both patients 
and their families. A survey was conducted to evaluate the disease burden, 
financial and quality of life impact of moderate to severe AD across 12 countries 
in the Asia Pacific region. In this analysis, we examine the costs incurred by 
households surveyed in managing pediatric atopic dermatitis. METHODS: A 
cross sectional survey was conducted in Australia, China, Hong Kong, India, 
Indonesia, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand, and 
Vietnam in January 2011. An online questionnaire was administered to 1028 
parents with children diagnosed with moderate to severe AD (aged 1 - 16 years). 
Household expenditure measured included expenses for health care services, 
treatment and investigations, cost of associated conditions and missed days of 
work. Local currency costs were converted to USD using 2011 exchange rates. 
RESULTS: Median household expenditure on AD was an average of USD 794 per 
annum, ranging from USD 258 in the Philippines to USD 1706 in Hong Kong. 
Across the various countries, spending on health care services and physician 
fees ranged from USD137 in India to USD622 in Singapore, while spending on 
treatments and investigations ranged from USD100 in Indonesia to USD721 in 
Hong Kong. Working mothers missed an average of 13.5 days of work in the past 
year to care for their children with AD. Missed work days ranged from 4.8 days in 
Korea to as high as 20 days in China. Median productivity losses ranged from 
USD34 in Vietnam to USD844 per year in Hong Kong. CONCLUSIONS: The results 
of the survey indicate that pediatric AD places considerable burden on 
household expenditure and productivity in the countries surveyed.  
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RSV HOSPITALIZATION IN INFANTS WITH NEUROMUSCULAR DISEASE IN THE 
CANADIAN REGISTRY OF SYNAGIS® (CARESS) FOLLOWING PROPHYLAXIS 
(2005-2012)  
Harimoto T1, Paes BA2, Mitchell I3, Li A1, Lanctot KL1 
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2McMaster University, Hamilton, ON, 
Canada, 3University of Calgary, Calgary, Alberta, Canada  
OBJECTIVES: Infants with neuromuscular impairment (NMI) are at high risk of 
severe respiratory syncytial virus (RSV) infection and may receive palivizumab 
prophylaxis during the RSV season. This study compared respiratory illness (RIH) 
and respiratory syncytial virus positive hospitalization (RSVH) rates in NMI 
infants who received prophylaxis versus those who were prophylaxed for 
standard indications (SD), and other underlying medical disorders (MD) through 
the Canadian Registry of Synagis® (CARESS). METHODS: CARESS is a 
prospective, observational study that was conducted in 32 sites across Canada 
for infants who received ≥1 dose of palivizumab prophylaxis during the 2005-
2012 RSV seasons. Compliance and RIH data were collected monthly. RESULTS:  
A total of 13,310 infants were enrolled in the database. 153 had NMI (1.2%), 11,239 
SD (84.4%), and 1,918 MD (14.4%). Enrolment age, gestational age, birth weight,  
as well as the proportions of Caucasians, daycare attendance, smoking exposure, 
siblings, multiple birth, >5 individuals in the household, and history of  
atopy, were significantly different (p<0.05) across the three groups. In the  
NMI group a smaller proportion received all of the expected injections compared 
to SD or MD groups (58.8% versus 65.8% and 67.9%, p=0.032). The prevalence of 
RIH and RSVH were much higher in the NMI group than SD or MD (RIH; 18.3% 
versus 9.6% and 5.9%, p<0.0005) (RSVH; 5.23% versus 1.56% and 1.21%, p<0.0005). 
Cox proportional hazard analysis showed an increased risk of RSVH in NMI 
patients compared to SD (hazard ratio=4.33, 95%CI 1.9-9.7, p<0.0005), after 
adjusting for covariates (injection compliance, daycare attendance, having 
siblings, exposure to smoking and crowding). CONCLUSIONS: Infants with NMI 
were found to be at higher risk of RIH and RSVH compared to SD or MD. These 
data support the need for palivizumab prophylaxis in NMI, as recommended by 
the American Academy of Pediatrics and other international pediatric advisory 
bodies.  
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KNOWLEDGE, BELIEF AND ATTITUDE OF GENERAL PRACTITIONERS IN 
PRESCRIBING ANTIBIOTICS FOR UPPER RESPIRATORY TRACT INFECTIONS  
Hassali MA1, Saleem F1, Haq N1, Aljadhey H2 
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OBJECTIVES: To evaluate the knowledge, attitude and beliefs of general 
practitioners’ (GPs) towards antibiotic prescribing for upper respiratory tract 
infections METHODS: A postal cross-sectional survey was conducted with 
randomly selected registered GPs in the state of Selangor, Malaysia. A 27-item 
questionnaire was developed and validated before the posting process. A follow 
up mail was posted after 3 weeks of the initial mail. RESULTS: One hundred and 
forty-four GPs responded to the survey but only one hundred and thirty nine  
GPs gave complete information, giving overall response rate of 37%. Fifty- 
nine percent of the respondents were male and were practicing for an average of 
21 years. 89.2% of the GPs agreed that antibiotic resistance is problematic  
and 88.5% of them concurred that prescription of antibiotics in primary-care  
can contribute to the problem. However, 56% GPs agreed that antibiotics  
may reduce the duration of URTIs. Many of the GPs (90%) believed that  
patients expect antibiotics from them but 78.4% GPs did not prescribed if they 
think the antibiotics are unnecessary for the patients. 95.7% GPs denied 
prescribing antibiotics for their financial benefits. First line treatment for 
uncomplicated URTI commonly chosen by the GPs was amoxicillin (53.2%). The 
most influential determinant of the GPs prescribing practice is the microbiology 
laboratory results (54%) followed by their past prescribing experience (41%). 
CONCLUSIONS: Overall knowledge of the GPs regarding antibiotic resistance was 
adequate but GPs may have incorrect knowledge of effect of antibiotics for 
uncomplicated URTIs. Understanding the belief and attitude in prescribing 
antibiotics is important to establish measures in reducing the escalation of 
antibiotic resistance.  
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TREATMENT OF ASTHMA USING ICS/LABA DRUGS PRE- AND POST-LABEL 
CHANGE  
Tempas K1, Schultz W2, Skovira M1 
1Catalina Health, Blue Bell, PA, USA, 2Catalina Health, Saddle Brook, NJ, USA  
OBJECTIVES: Determine whether treatment of asthma with drug therapy in 
adults has changed since the FDA label change in 2010. This label change 
stipulates ICS/LABA drugs are to be used only if a patient is uncontrolled on a 
plain ICS, and then for the shortest period possible after achieving control. 
METHODS: Catalina Health receives data from a nationally representative 
sample of pharmacy chains, representing approximately 40% of all national 
retail prescription volume, and comprised of over 130 million unique patients. 
Data are captured daily from the pharmacies, are fully HIPAA compliant, 
longitudinal, and not projected. Patient cohorts included patients initiating 
ICS/LABA therapy as their first controller medication, before and after the label 
change. Both cohorts were followed for a year to determine if fills of ICS/LABA 
medication as initial therapy had declined and if days of therapy had shortened. 
RESULTS: Patient cohort consisted of 7,040 patients who initiated ICS/LABA 
therapy during November, 2008 and 6,971 patients who initiated ICS/LABA 
therapy during November, 2011. There was no overlap of patients between the 
two groups. Cohorts had no prior fills of ICS/LABAs or a plain ICS drug. Patients 
were between the ages of 12 and 40 to eliminate children and COPD patients. 
Patients with fills of COPD drugs (anticholinergics or xanthines) were excluded. 
Patients with only one fill of an ICS/LABA and no fills of an ICS during the year 
were excluded (pneumonia patients).Comparing the two cohorts, the key 
findings were Average Days of Therapy on the ICS/LABA declined from 78.8 to 
76.6 (p-value=.068). Average fills of an ICS/LABA declined from 2.57 to 2.45 (p-
value=.002). CONCLUSIONS: The differences between the cohorts are small, but 
are statistically significant, indicating the label change is being adopted in the 
management of asthma patients.  
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FACTORS IMPACTING CONSUMERS' EXPECTED LIKELIHOOD AND EXTENT OF 
INFORMATION SEARCH BEHAVIORS FOR A MEDICAL CONDITION AND A 
PHARMACEUTICAL TREATMENT  
Liu Y, Fincham JE, Marken PA, Sperry ML 
The University of Missouri - Kansas City, Kansas City, MO, USA  
OBJECTIVES: To identify factors impacting consumers’ expected likelihood and 
extent of information search behaviors for a medical condition and a 
pharmaceutical treatment. METHODS: A telephone interview was administered 
to a random-digit-dialed sample of 2186 adult consumers in a southern U.S. 
state. Measurements included expected likelihood of information search for  
a medical condition and a pharmaceutical treatment (yes/no), expected extent  
of such behaviors if the answer is a yes (5-point scale), types of medical 
condition, types of pharmaceutical treatment, types of information sources, 
frequency of past information search, self-rated health (4-point scale), 
extraversion (5-point scale), and demographics. Two logistic regressions were 
conducted, in which the dependent variables were the expected likelihood for  
a medical condition and a pharmaceutical treatment, respectively; and 
independent variables were health, extraversion, and demographics. Two OLS 
regressions were also conducted, in which the dependent variables were the 
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expected extent for a medical condition and a pharmaceutical treatment, 
respectively; and the independent variables were types of medical condition  
or pharmaceutical treatment, types of information sources, frequency of past 
information search, health, extraversion, gender, and metropolitan statistical 
area. RESULTS: A total of 505 consumers yielded complete interviews, with  
a cooperation rate of 37.4%. On average, they were 57 years old, and 61% of them 
were female. Twenty percent of them had expectations of seeking information 
for a medical condition, and 14% for a pharmaceutical treatment. All regressions 
were significant (p<0.01). Health and gender were significant predictors  
for expected likelihood, and health and extraversion were significant predictors 
for expected extent (p<0.05). CONCLUSIONS: As perceived health status 
worsened, consumers were not only more likely to search for information, but 
also to a larger degree. Women were more likely to search for information, and 
those who were outgoing tended to perform information search to a larger 
degree.  
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DIFFERENT STAKEHOLDER PERSPECTIVES ON PHARMACOGENOMIC TESTING  
Patel H, Ursan I, Zueger P, Pickard AS 
University of Illinois at Chicago, Chicago, IL, USA  
OBJECTIVES: Although the potential benefits of pharmacogenomic (PG) testing 
may be readily evident, there are numerous concerns creating barriers to its 
implementation. The purpose of our study was to compare various stakeholder 
attitudes and concerns toward PG testing as identified from the literature. A sub-
aim was to understand issues with PG testing identified by underrepresented 
groups. METHODS: Using specific keywords, we conducted a systematic 
literature search of electronic databases including PubMed, IPA, CINAHL, and 
EMBASE. Articles that evaluated the attitudes and beliefs about PG testing were 
included. Concerns identified in the studies were categorized into themes 
(ancillary information-related, clinical, economical, educational, ethical/legal, 
medical mistrust, and operational), and summarized according to stakeholder 
group (patients, general public, providers, payers and others). RESULTS: Of 1483 
citations identified in the initial search, 38 studies that presented 41 perspectives 
met the inclusion criteria, employing methods of eliciting perceptions via 
surveys, focus groups and interviews. Overall, there were 15 studies focusing on 
providers, 9 on general public, 9 on patients, and 4 on payers, and 4 on other 
stakeholder perspectives. Studies of the general public most commonly 
identified issues related to medical mistrust (n=5), education (n=5) and 
operations (n=5). The most prevalent issues from the patient perspective 
included ethical/legal (n=6) and economical (n=5). Clinical (n=11) and educational 
(n=11) issues related to PG testing were recognized as frequent among the 
providers. Among the payer perspective, operational (n=4) and clinical (n=3) 
issues were prominent. In the underrepresented groups, concerns of medical 
mistrust and economical issues were notably higher compared to other groups. 
CONCLUSIONS: While the number of studies, assessing attitudes and concerns 
of various stakeholders, has increased over the last five years, the fundamental 
issues remain unchanged. Improved understanding of such issues may help 
strengthen the uptake of pharmacogenomic testing in clinical practice and lead 
to better health outcomes.  
 
PHP3  
PUBLIC ENGAGMENT MECHANISMS IN HEALTH TECHNOLOGY ASSESSMENT 
(HTA): AN EARLY ASSESSMENT OF CANADA'S NATIONAL HTA PUBLIC 
ENGAGEMENT INITIATIVES  
Tran JB 
Double Helix Consulting, London, UK  
OBJECTIVES: To address questions about the importance of public (patients, 
patient groups, etc) engagement in HTA processes with the objective to – 1) 
explore ideas regarding the use of public engagement in decision making 
processes (specifically coverage decisions), and 2) contextualise some of  
the main arguments found by assessing the Canadian Agency for Drugs and 
Technologies in Health’s (CADTH) current public engagement mechanisms for  
its Common Drug Review (CDR). METHODS: A literature search was performed to 
identify key theoretical arguments for and against public engagement in HTA 
processes. The search was mainly focused on sources from Canada and the UK. 
A review of CADTH’s website was conducted for technology appraisals 
completed by the CDR process since the start of its public engagement initiatives 
(to mid-August 2012). RESULTS: Key arguments for public engagement in 
decision making include: transparency, accountability, equity, and creating a 
patient-centric health system. With the CDR, the percentage of appraisals 
conducted for coverage decisions that included public (patient group) input was 
48%. The lack of engagement from patient groups on half of the appraisals 
highlights some of the key challenges of public engagement (e.g., lack of 
awareness, lack of budget). Furthermore, the documents reviewed showed that 
some indications received more responses than others (e.g., epilepsy, 
schizophrenia). This may potentially result in some underfunded patient groups 
feeling disempowered, which is a risk of engagement. CONCLUSIONS:  
The findings of the study support initiatives that encourage the engagement  
of the public so that decision makers can better incorporate the values held  
by citizens. However, the relative value of doing so will vary. To ensure that 
public engagement in HTA is appropriate and fair, Canada and other 
jurisdictions must have political will, dedicated resources, and the motivation to 
facilitate educational activities that support active engagement from all types of 
public.  
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PRICE ELASTICITY AND MEDICATION USE: COST-SHARING IN MULTIPLE 
CHRONIC CONDITIONS  
Gatwood J1, Gibson TB2, Chernew M3, Farr A4, Vogtmann E5, Fendrick M6 
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OBJECTIVES: To examine the impact of cost-sharing on the demand for 
medication across several classes of prescription medications indicated to treat 
chronic conditions. METHODS: Data from the 2005-2009 MarketScan Commercial 
Claims and Encounters databases were used to evaluate prescription fills across 
10 categories of medications. The date of first fill served as the index date for 
each subject and patterns of use were analyzed for at least seven continuous 
calendar quarters within the study window. Cost sharing, expressed as a price 
index for each medication class, was the main explanatory variable to examine 
price elasticity of demand. This index was based on the average cost-sharing 
amount per prescription and was weighted using the national proportion of 
generic and brand medication within each drug category. Negative binomial 
generalized estimating equations models were constructed to examine 
medication fills; standard demographic variables were used to control for 
confounding. RESULTS: Prescription fills per enrollee ranged from 0.01 (smoking 
deterrents) to 0.23 (Statins) and the average spending for medications showed 
considerable variability: those taking thyroid hormone reported an average 
expenditure of $31.29 while those on antiplatelets had an average expenditure of 
$330.38. Additionally, the share of generic drug use within each category ranged 
from 4.7% (smoking deterrents) to 88.4% (NSAIDs/Opioids). Estimates from the 
negative binomial models revealed that the price elasticity of demand ranged 
from -0.015 to -0.157 within the 10 categories of medications (p<0.05 for 9 of 10 
categories). Demand for smoking deterrents proved to be the most price elastic 
of drug categories (-0.157), while NSAIDs/Opioids were observed to be relatively 
price inelastic (-0.015). CONCLUSIONS: The price elasticity of demand varied 
considerably by medication category, suggesting that the influence of cost-
sharing on medication use may be related to characteristics inherent to each 
medication class or underlying condition.  
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AN ANALYSIS OF THE RELATIONSHIP BETWEEN GROWTH IN PATIENT COST 
SHARING DUE TO BENEFIT DESIGN SHIFTS AND DIAGNOSTIC PRICING AND 
SPENDING  
Abraham J, Garfield S, Sulham K 
GfK Bridgehead, Wayland, MA, USA  
OBJECTIVES: Consumers are shouldering an increasing percentage of health care 
expenditures through cost-sharing mechanisms embedded in benefit design 
structures. As a result, many patients are paying out-of-pocket for some or all of 
the costs associated with diagnostic testing. Traditionally, diagnostic companies 
have focused on demonstrating value to payers with the goal of achieving 
adequate pricing and reimbursement. Though this approach will remain 
necessary, patients are an increasingly critical stakeholder in determining 
whether a diagnostic’s value supports the resulting out-of-pocket costs. This 
study examined how out-of-pocket expenditures by individuals, national health 
expenditures (NHE) on diagnostics, and the price index for diagnostics grew 
between 2005 and 2011. METHODS: A systematic review of published literature 
related to health care expenditure, health insurance coverage, diagnostic pricing, 
and benefit design was performed. In follow-up, data from the Centers for 
Disease Control and Prevention, Bureau of Labor Statistics, Employer Benefits 
Health Survey, and diagnostic industry reports were reviewed to examine growth 
rates over the study period. Basic statistical methods were employed to 
determine how average annual growth rates within each segment relate to other 
variables being considered. RESULTS: The proportion of individuals in America 
with high-deductible health plans has increased 475% in the last six years. This 
correlates to over 25 million Americans responsible for at least $2000 in 
deductible costs in addition to coinsurance and co-pays. During this period, 
pricing of diagnostics only rose at an average annual rate of 1.0%. Overall 
spending on health care increased while diagnostics expenditure remained 
consistent at 6% of NHE. CONCLUSIONS: As health care continues to transform, 
the demand for high quality diagnostics will continue to grow. However, the 
increasing financial burden borne by individuals will lead to increased price 
sensitivity. Novel technologies will need to demonstrate value and clinical utility 
not only to payers, but to patients, to achieve pricing and reimbursement.  
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RACIAL DISPARITY IN DURATION OF PATIENTS' VISITS TO THE EMERGENCY 
DEPARTMENT: TEACHING VERSUS NON-TEACHING HOSPITALS  
Wong H, Karaca Z 
Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA  
OBJECTIVES: Racial disparity in duration of patients’ visits to emergency 
departments (EDs) have not been well documented. This study explores the 
racial disparity in duration of routine visits to EDs at teaching and non-teaching 
hospitals. METHODS: Retrospective data analyses and multivariate regression 
analyses were performed to investigate the racial disparity in duration of routine 
ED visits at teaching and non-teaching hospitals. Duration for each visit was 
computed by taking the difference between admission and discharge times. The 
Healthcare Cost and Utilization Project (HCUP) State Emergency Department 
Databases (SEDD) were used in the analyses. The data include 4.3 million routine 
ED visits encountered in Arizona, Massachusetts, and Utah during 2008. SEDD 
provide detailed diagnoses, procedures, total charges, patient demographics, and 
admission and discharge time for each visit. We linked SEDD files with American 
Hospital Association Annual Survey Database, Trauma Information Exchange 
Program Database and Area Resource File to obtain hospital and area level 
characteristics. RESULTS: The mean duration for a routine ED visit was 238 
